|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
1,770,000,000 |
Market
Cap: |
300.33(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$132.51 - $182.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 560 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
80,031 |
461,916 |
540,416 |
831,596 |
Total Sell Value |
$14,256,265 |
$81,646,316 |
$93,320,391 |
$138,453,569 |
Total People Sold |
2 |
9 |
9 |
12 |
Total Sell Transactions |
2 |
11 |
13 |
29 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Saleki-Gerhardt Azita |
SVP, Operations |
|
2013-03-08 |
4 |
S |
$37.50 |
$18,600 |
D/D |
(496) |
59,272 |
|
- |
|
Leonard John M. |
SVP, Chief Scientific Officer |
|
2013-03-08 |
4 |
S |
$37.50 |
$1,048,432 |
D/D |
(27,949) |
107,320 |
|
- |
|
Alban Carlos |
EVP, Commercial Operations |
|
2013-02-28 |
4 |
D |
$36.73 |
$476,021 |
D/D |
(12,960) |
146,835 |
|
- |
|
Gonzalez Richard A |
Chairman of the Board and CEO |
|
2013-02-28 |
4 |
D |
$36.73 |
$283,409 |
D/D |
(7,716) |
296,306 |
|
- |
|
Saleki-Gerhardt Azita |
SVP, Operations |
|
2013-02-28 |
4 |
D |
$36.73 |
$54,324 |
D/D |
(1,479) |
59,768 |
|
- |
|
Hurwich Thomas A. |
VP, Controller |
|
2013-02-28 |
4 |
D |
$36.73 |
$80,475 |
D/D |
(2,191) |
48,418 |
|
- |
|
Chase William J |
EVP, Chief Financial Officer |
|
2013-02-28 |
4 |
D |
$36.73 |
$193,200 |
D/D |
(5,260) |
138,656 |
|
- |
|
Leonard John M. |
SVP, Chief Scientific Officer |
|
2013-02-28 |
4 |
D |
$36.73 |
$345,519 |
D/D |
(9,407) |
135,269 |
|
- |
|
Schumacher Laura J |
EVP, Bus.Dev.,Ext.Aff.&GC |
|
2013-02-28 |
4 |
D |
$36.73 |
$716,859 |
D/D |
(19,517) |
244,784 |
|
- |
|
Leonard John M. |
SVP, Chief Scientific Officer |
|
2013-02-19 |
4 |
D |
$37.58 |
$952,465 |
D/D |
(25,345) |
148,981 |
|
- |
|
Leonard John M. |
SVP, Chief Scientific Officer |
|
2013-02-19 |
4 |
OE |
$27.29 |
$809,267 |
D/D |
29,650 |
174,326 |
|
- |
|
Alban Carlos |
EVP, Commercial Operations |
|
2013-02-19 |
4 |
D |
$37.58 |
$369,261 |
D/D |
(9,826) |
159,795 |
|
- |
|
Leonard John M. |
SVP, Chief Scientific Officer |
|
2013-02-19 |
4 |
D |
$37.58 |
$299,964 |
D/D |
(7,982) |
144,676 |
|
- |
|
Saleki-Gerhardt Azita |
SVP, Operations |
|
2013-02-19 |
4 |
D |
$37.58 |
$15,821 |
D/D |
(421) |
61,247 |
|
- |
|
Schumacher Laura J |
EVP, Bus.Dev.,Ext.Aff.&GC |
|
2013-02-19 |
4 |
D |
$37.58 |
$564,602 |
D/D |
(15,024) |
264,301 |
|
- |
|
Hurwich Thomas A. |
VP, Controller |
|
2013-02-19 |
4 |
D |
$37.58 |
$85,119 |
D/D |
(2,265) |
50,609 |
|
- |
|
Chase William J |
EVP, Chief Financial Officer |
|
2013-02-19 |
4 |
D |
$37.58 |
$109,433 |
D/D |
(2,912) |
143,916 |
|
- |
|
Gonzalez Richard A |
Chairman of the Board and CEO |
|
2013-02-19 |
4 |
D |
$37.58 |
$117,625 |
D/D |
(3,130) |
304,022 |
|
- |
|
Richmond Timothy J. |
SVP, Human Resources |
|
2013-02-19 |
4 |
D |
$37.58 |
$17,437 |
D/D |
(464) |
90,165 |
|
- |
|
Richmond Timothy J. |
SVP, Human Resources |
|
2013-02-18 |
4 |
D |
$37.58 |
$18,640 |
D/D |
(496) |
90,629 |
|
- |
|
Richmond Timothy J. |
SVP, Human Resources |
|
2013-02-17 |
4 |
D |
$37.58 |
$20,068 |
D/D |
(534) |
91,125 |
|
- |
|
Alban Carlos |
EVP, Commercial Operations |
|
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
56,700 |
169,621 |
|
- |
|
Leonard John M. |
SVP, Chief Scientific Officer |
|
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
30,360 |
152,658 |
|
- |
|
Saleki-Gerhardt Azita |
SVP, Operations |
|
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
36,480 |
61,668 |
|
- |
|
Schumacher Laura J |
EVP, Bus.Dev.,Ext.Aff.&GC |
|
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
71,230 |
279,325 |
|
- |
|
765 Records found
|
|
Page 30 of 31 |
|
|